BioNTech SE
Close on Oct 19, 2026
About BioNTech
Biological Products, (No Diagnostic Substances), SIC 2836
BioNTech is a biotechnology company focused on developing immunotherapies and specialized medical solutions. Its operations encompass cell and gene therapies, delivery technologies, peptide research, diagnostics, and artificial intelligence-driven discovery. The enterprise derives revenue from COVID-19 vaccines, licensing agreements, and external product sales. Its commercial relationships and key counterparties include major pharmaceutical collaborators, notably Pfizer and Bristol Myers Squibb, as well as institutional clients such as the German Federal Ministry of Health.
The group maintains an international footprint comprising research, clinical, and production activities across numerous countries, including Germany, the United States, the United Kingdom, China, Australia, Austria, Belgium, France, Ireland, Israel, Rwanda, Singapore, Spain, Switzerland, Tunisia, and Turkey. Its core operations and manufacturing entities are concentrated in Germany, including facilities in Marburg and Idar-Oberstein.
Summary of the business section of BioNTech's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BioNTech SE
- Founded
- 2008
- Headquarters
- Mainz, 2M
- Address
- An Der Goldgrube 12 55131
- Phone
- 0049613190840
- Website
- biontech.de
- Employees
- 500, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- 2M
- Fiscal year ends
- December 31
- Auditor
- EY GmbH & Co. KG Wirtschaftsprufungsgesellschaft, Cologne, Germany
Stock & identifiers
- Ticker
- BNTX
- Exchange
- Nasdaq
- IPO date
- Oct 11, 2019
- Shares outstanding
- 251M, Mar 27, 2026
- Filer category
- Large accelerated filer
- SEC CIK
- 1776985
- CUSIP
- 09075V102
- ISIN
- US09075V1026
- LEI
- 894500UZJ5LG1F8J1U58
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ugur Sahin | Chief Executive Officer | 39,432,320 |
| Annemarie Hanekamp | Chief Commercial Officer | – |
| James Timothy Patrick Ryan | See remarks. | 4,795 |
| Kylie Jimenez | Chief People Officer | – |
| Gomez Ramon Zapata | Chief Financial Officer | – |
| Sierk Poetting | Chief Operating Officer | 540,901 |
| Ozlem Tureci | Chief Medical Officer | – |
| Iris Katharina Low-Friedrich | Director | – |
| Susanne Schaffert | Director | – |
| Nicola Claire Blackwood | Director | – |
| Anja Morawietz | Director | 240 |
| Rudolf Staudigl | Director | 400 |
| Helmut Wolfgang Jeggle | Director | 989,267 |
| Michael Motschmann | Director | – |
| Ulrich Wandschneider | Director | 1,927 |
Employees
Headcount reported in annual reports
“Around 500 staff members are employed at”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 21, 2025 | Tender offer | Third-party tender offer for the company's shares |
| Aug 11, 2025 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Apr 1, 2020 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Oct 11, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 7, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |